Correlation of decreased survival and IL-18 in bone metastasis

Internal Medicine

Volumn 48, Issue 10, 2009, Pages 763-773

  Okamoto, Masaki ^a   Azuma, Koichi ^a   Hoshino, Tomoaki ^a   Imaoka, Haruki ^a   Ikeda, Jiro ^a   Kinoshita, Takashi ^a   Takamori, Shinzo ^a   Ohshima, Koichi ^a   Edakuni, Nobutaka ^a   Kato, Seiya ^b   Iwanaga, Tomoaki ^a   Aizawa, Hisamichi ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF THE RYUKYUS   (Japan)

Author keywords

IL 18; Non small cell lung cancer

Indexed keywords

ANTINEOPLASTIC AGENT; GAMMA INTERFERON; INTERLEUKIN 18; THIOREDOXIN 1;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BONE METASTASIS; CANCER CELL; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN LOCALIZATION; SURVIVAL RATE; SURVIVAL TIME; TISSUE DISTRIBUTION;

ADENOCARCINOMA; AGED; BONE AND BONES; BONE NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INTERFERON-GAMMA; INTERLEUKIN-18; JAPAN; LUNG; LUNG NEOPLASMS; MALE; MIDDLE AGED; SURVIVAL ANALYSIS; THIOREDOXINS;

EID: 67649961711     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.48.1851     Document Type: Article

References (44)

1. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346: 92-98, 2002.
2. Street SE, Cretney E, Smyth MJ. Perforin and interferon-gamma activities independently control tumor initiation, growth, and metastasis. Blood 97: 192-197, 2001.
3. Dighe AS, Richards E, Old LJ, Schreiber RD. Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN gamma receptors. Immunity 1: 447-456, 1994.
4. Lissoni P, Barni S, Rovelli F, Tancini G. Lower survival in metastatic cancer patients with reduced interleukin-2 blood concentrations. Preliminary report. Oncology 48: 125-127, 1991.
5. Lissoni P, Rovelli F, Fumagalli L, Mauri E, Barni S. Tancini G. Increased blood concentrations of interleukin-12 are associated with a longer survival in untreatable metastatic solid tumor patients: preliminary observations. Int J Biol Markers 12: 125-127, 1997.
6. Nakanishi K, Yoshimoto T, Tsutsui H, Okamura H. Interleukin-18 regulates both th1 and th2 responses. Annu Rev Immunol 19: 423-474, 2001.
7. Kitasato Y, Hoshino T, Okamoto M, et al. Enhanced expression of interleukin-18 and its receptor in idiopathic pulmonary fibrosis. Am J Respir Cell Mol Biol 31: 619-625, 2004.
8. Kawakami K, Qureshi MH, Zhang T, Okamura H, Kurimoto M, Saito A. IL-18 protects mice against pulmonary and disseminated infection with Cryptococcus neoformans by inducing IFN-gamma production. J Immunol 159: 5528-5534, 1997.
9. Dinarello CA. IL-18: A TH1-inducing, proinflammatory cytokine and new member of the IL-1 family. J Allergy Clin Immunol 103: 11-24, 1999.
10. Kanai T, Watanabe M, Okazawa A, et al. Interleukin 18 is a potent proliferative factor for intestinal mucosal lymphocytes in Crohn's disease. Gastroenterology 119: 1514-1523, 2000.
11. Okamoto M, Kato S, Oizumi K, et al. Interleukin 18 (IL-18) in synergy with IL-2 induces lethal lung injury in mice: a potential role for cytokines, chemokines, and natural killer cells in the pathogenesis of interstitial pneumonia. Blood 99: 1289-1298, 2002.
12. Kawase Y, Hoshino T, Yokota K, et al. Exacerbated and prolonged allergic and non-allergic inflammatory cutaneous reaction in mice with targeted interleukin-18 expression in the skin. J Invest Dermatol 121: 502-509, 2003.
13. Hoshino T, Kato S, Oka N, et al. Pulmonary inflammation and emphysema: Role of the cytokines IL-18 and IL-13. Am J Respir Crit Care Med 176: 49-62, 2007.
14. Imaoka H, Hoshino T, Takei S, et al. Interleukin-18 production and pulmonary function in COPD. Eur Respir J 31: 287-297, 2008.
15. Park CC, Morel JC, Amin MA, Connors MA, Harlow LA, Koch AE. Evidence of IL-18 as a novel angiogenic mediator. J Immunol 167: 1644-1653, 2001.
16. Fukumoto H, Nishio M, Nishio K, et al. Interferon-gammainducing factor gene transfection into Lewis lung carcinoma cells reduces tumorigenicity in vivo. Jpn J Cancer Res 88: 501-505, 1997.
17. Ohtsuki T, Micallef MJ, Kohno K, Tanimoto T, Ikeda M, Kurimoto M. Interleukin 18 enhances Fas ligand expression and induces apoptosis in Fas-expressing human myelomonocytic KG-1 cells. Anticancer Res 17: 3253-3258, 1997.
18. Takubo T, Kumura T, Nakao T, et al. Comparative study on complete remission rate and overall survival in three groups classified based on the serum interleukin-18 level in non-Hodgkin's lymphoma patients. Acta Haematol 104: 220-222, 2000.
19. Kawabata T, Ichikura T, Majima T, et al. Preoperative serum interleukin-18 level as a postoperative prognostic marker in patients with gastric carcinoma. Cancer 92: 2050-2055, 2001.
20. Tagaya Y, Maeda Y, Mitsui A, et al. ATL-derived factor (ADF), an IL-2 receptor/Tac inducer homologous to thioredoxin; possible involvement of dithiol-reduction in the IL-2 receptor induction. Embo J 8: 757-764, 1989.
21. Nakamura H, Nakamura K, Yodoi J. Redox regulation of cellular activation. Annu Rev Immunol 15: 351-369, 1997.
22. Hoshino T, Nakamura H, Okamoto M, et al. Redox-active protein thioredoxin prevents proinflammatory cytokine- or bleomycininduced lung injury. Am J Respir Crit Care Med 168: 1075-1083, 2003.
23. Kinoshita T, Hoshino T, Imaoka H, et al. Thioredoxin prevents the development and progression of elastase-induced emphysema. Biochem Biophys Res Commun 354: 712-719, 2007.
24. Kakolyris S, Giatromanolaki A, Koukourakis M, et al. Thioredoxin expression is associated with lymph node status and prognosis in early operable non-small cell lung cancer. Clin Cancer Res 7: 3087-3091, 2001.
25. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216, 2000.
26. Ferrucci L, Corsi A, Lauretani F, et al. The origins of age-related proinflammatory state. Blood 105: 2294-2299, 2005.
27. Gunel N, Coskun U, Sancak B, Gunel U, Hasdemir O, Bozkurt S. Clinical importance of serum interleukin-18 and nitric oxide activities in breast carcinoma patients. Cancer 95: 663-667, 2002.
28. Naumnik W, Chyczewska E, Kovalchuk O, Talalaj J, Izycki T, Panek B. Serum levels of interleukin-18 (IL-18) and soluble interleukin-2 receptor (sIL-2R) in lung cancer. Rocz Akad Med Bialymst 49: 246-251, 2004.
29. Vidal-Vanaclocha F, Mendoza L, Telleria N, et al. Clinical and experimental approaches to the pathophysiology of interleukin-18 in cancer progression. Cancer Metastasis Rev 25: 417-434, 2006.
30. Golab J. Interleukin 18 - interferon gamma inducing factor - a novel player in tumour immunotherapy? Cytokine 12: 332-338, 2000.
31. Hoshino T, Wiltrout RH, Young HA. IL-18 is a potent coinducer of IL-13 in NK and T cells: a new potential role for IL-18 in modulating the immune response. J Immunol 162: 5070-5077, 1999.
32. Hoshino T, Yagita H, Ortaldo JR, Wiltrout RH, Young HA. In vivo administration of IL-18 can induce IgE production through Th2 cytokine induction and up-regulation of CD40 ligand (CD154) expression on CD4+ T cells. Eur J Immunol 30: 1998-2006, 2000.
33. De Vita F, Orditura M, Galizia G, et al. Serum interleukin-10 levels in patients with advanced gastrointestinal malignancies. Cancer 86: 1936-1943, 1999.
34. Lissoni P, Brivio F, Rovelli F, et al. Serum concentrations of interleukin-18 in early and advanced cancer patients: enhanced secretion in metastatic disease. J Biol Regul Homeost Agents 14: 275-277, 2000.
35. Nakata A, Tsujimura T, Sugihara A, et al. Inhibition by interleukin 18 of osteolytic bone metastasis by human breast cancer cells. Anticancer Res 19: 4131-4138, 1999.
36. Iwasaki T, Yamashita K, Tsujimura T, et al. Interleukin-18 inhibits osteolytic bone metastasis by human lung cancer cells possibly through suppression of osteoclastic bone-resorption in nude mice. J Immunother (1997) 25 uppl 1: S52-60, 2002.
37. Udagawa N, Horwood NJ, Elliott J, et al. Interleukin-18 (interferon-gamma-inducing factor) is produced by osteoblasts and acts via granulocyte/macrophage colony-stimulating factor and not via interferon-gamma to inhibit osteoclast formation. J Exp Med 185: 1005-1012, 1997.
38. Kawase Y, Hoshino T, Yokota K, et al. Bone malformations in interleukin-18 transgenic mice. J Bone Miner Res 18: 975-983, 2003.
39. Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie MT, Martin TJ. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev 20: 345-357, 1999.
40. Makiishi-Shimobayashi C, Tsujimura T, Iwasaki T, et al. Interleukin-18 up-regulates osteoprotegerin expression in stromal/osteoblastic cells. Biochem Biophys Res Commun 281: 361-366, 2001.
41. Cao Q, Cai W, Niu G, et al. Multimodality imaging of IL-18-binding protein-Fc therapy of experimental lung metastasis. Clin Cancer Res 14: 6137-6145, 2008.
42. Voorzanger-Rousselot N, Juillet F, Mareau E, Zimmermann J, Kalebic T, Garnero P. Association of 12 serum biochemical markers of angiogenesis, tumour invasion and bone turnover with bone metastases from breast cancer: a crossectional and longitudinal evaluation. Br J Cancer 95: 506-514, 2006.
43. Leeming DJ, Koizumi M, Byrjalsen I, Li B, Qvist P, Tanko LB. The relative use of eight collagenous and noncollagenous markers for diagnosis of skeletal metastases in breast, prostate, or lung cancer patients. Cancer Epidemiol Biomarkers Prev 15: 32-38, 2006.
44. Soini Y, Kahlos K, Napankangas U, et al. Widespread expression of thioredoxin and thioredoxin reductase in non-small cell lung carcinoma. Clin Cancer Res 7: 1750-1757, 2001.